试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum
编号:NCT05343754登记状态:提前终止企业 / 申办者:Erasmus Medical Center
药物 / 成分:Hyperbaric oxygen、Control group
登记的停止原因(原文):Due to low recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
编号:NCT05430854登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Daxdilimab
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
编号:NCT05567783登记状态:提前终止企业 / 申办者:Vir Biotechnology, Inc.
药物 / 成分:VIR-2482 (450 mg)、VIR-2482 (1200 mg)、Placebo
登记的停止原因(原文):VIR-2482 1200 mg did not demonstrate efficacy versus placebo in the primary analysis of the primary endpoint
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
编号:NCT05641545登记状态:提前终止企业 / 申办者:SLK Kliniken Heilbronn GmbH
药物 / 成分:IVAC
登记的停止原因(原文):Premature discontinuation due to üoor participant recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
编号:NCT05655299登记状态:提前终止企业 / 申办者:Ventyx Biosciences, Inc
药物 / 成分:VTX958 Dose A、VTX958 Dose B、VTX958 Dose C、VTX958 Dose D
登记的停止原因(原文):Business Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
编号:NCT05679388登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:Relugolix Pill、Ritonavir、Itraconazole
登记的停止原因(原文):Terminated by the PI
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
编号:NCT05682170登记状态:提前终止企业 / 申办者:K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
药物 / 成分:ZN-d5 ZN-c3、ZN-c3
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
编号:NCT05695378登记状态:提前终止企业 / 申办者:Kainos Medicine Inc.
药物 / 成分:KM-819、Placebo
登记的停止原因(原文):Sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
编号:NCT06056596登记状态:提前终止企业 / 申办者:University of Wisconsin, Madison
药物 / 成分:Lamivudine 300 MG、Placebo
登记的停止原因(原文):Treatment approach changed, and insufficient population
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
编号:NCT01904253登记状态:提前终止企业 / 申办者:Taiho Oncology, Inc.
药物 / 成分:TAS-102、Amrubicin (Japan)、Topotecan (Japan/Europe)
登记的停止原因(原文):The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms
查看官方原始记录 ↗